Aeolus Pharmaceuticals, Inc., published additional data demonstrating the efficacy of AEOL 10150 as a medical countermeasure to sulfur mustard gas exposure on Monday.
The data showed that treatment with AEOL 10150 48 hours after exposure to sulfur mustard gas improved survival rates from 36 percent to 88 percent, decreased airway casts by 69 percent, restored TGF-beta1 to control levels, improved blood oxygenation, and decreased markers of oxidative stress.
Additional data in the report showed increased blood oxygen saturation by more than 10 percent and improved clinical scores of lung health by 57 percent.
The studies for the report were undertaken by Dr. Brian Day, vice chair of research at National Jewish Health, in collaboration with the University of Colorado and the U.S. Army Medical Institute for Chemical Defense. The CounterACT program, the National Institutes of Health Office of the Director and the National Institute of Environmental Health Sciences all provided funding for the studies. The data was published online in the journal Toxicological Sciences.
“AEOL 10150 significantly improves survival by reducing inflammation and fibrosis in the lungs after exposure to a range of chemical insults and radiation exposure,” John L. McManus, president and chief executive officer of Aeolus Pharmaceuticals, said. “The data presented in this publication provides further support for the potential of AEOL 10150 as a medical countermeasure for sulfur mustard gas exposure, as well as mechanistic insights into how the drug protects the lungs from other insults such as radiation and in clinical applications such as idiopathic pulmonary fibrosis and radiation and chemotherapy for cancer patients.”